Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022

Read More

Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

Read More

Ryvu Therapeutics’ development plans for 2022-2024

Read More

Change of the date of publication of the periodic report for the first half of 2022

Read More

Conclusion of a financing agreement with the European Investment Bank

Read More

Changes in Ryvu’s Management Board

Read More

Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program

Read More

Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies

Read More

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022

Read More

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.

Read More

Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)

Read More

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

Read More

Ryvu Therapeutics S.A. Q1 2022 Financial Report

Read More

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022

Read More

Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting

Read More

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

Read More

Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting

Read More

Publication dates for periodic reports in 2022

Read More

Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center

Read More